Basic Study
Copyright ©The Author(s) 2020.
World J Stem Cells. Sep 26, 2020; 12(9): 1032-1049
Published online Sep 26, 2020. doi: 10.4252/wjsc.v12.i9.1032
Figure 6
Figure 6 Inhibitory effects of mesenchymal stem cells therapy on graft-versus-host disease severity. A-C: NOG mice were administered 200 cGy of total body irradiation before transplantation of human peripheral blood mononuclear cells (2 × 107). At days 0, 7 and 14 after transplantation, mice were administered with umbilical cord-derived mesenchymal stem cells or bone marrow-derived mesenchymal stem cells (1 × 105). All NOG mice were monitored for survival (A), clinical signs of graft-versus-host disease (B) and weight (C). BM-MSC: Bone marrow-derived mesenchymal stem cells; GVHD: Graft-versus-host disease; UC-MSC: Umbilical cord-derived mesenchymal stem cells.